Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AS1501 injection in acute-on-chronic liver failure
ChiCTR2500100052Phase 2Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of AS1501 in acute-on-chronic liver failure (ACLF), sponsored by Shenzhen Third People's Hospital. Primary endpoint: Incidence of adverse events and serious adverse events. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
AS1501
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on ChiCTR2500100052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100052.